(C2H5)(C(p-trimethylacetoxyphenyl))2OCH2CO[(η5-C5H4)FeCp] | 933037-59-3

• 英文名称: (C2H5)(C(p-trimethylacetoxyphenyl))2OCH2CO[(η5-C5H4)FeCp]
• CAS: 933037-59-3
• 化学式: C₄₄H₄₆FeO₆
• 分子量: 726.693
• InChiKey: IOFDWRCBHDVYEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

反应信息

• 作为反应物：
  描述：

  (C2H5)(C(p-trimethylacetoxyphenyl))2OCH2CO[(η5-C5H4)FeCp] 在 NaOH 作用下， 以 四氢呋喃 、 水 为溶剂， 以72%的产率得到(C2H5)(C(p-hydroxyphenyl))2OCH2CO[(η5-C5H4)FeCp]
  参考文献：
  名称：

  Organometallic analogues of tamoxifen: Effect of the amino side-chain replacement by a carbonyl ferrocenyl moiety in hydroxytamoxifen

  摘要：

  Since the widely prescribed selective estrogen receptor modulator (SERM) tamoxifen encounters growing cases of resistance in long-term treatments, alternative drugs with different therapeutic scopes have to be developed. Many investigators have modified the triphenylethylene scaffold, but very few have changed its amino side chain, essential for the antiestrogenic activity. For the first time, a lipophilic and stable organometallic entity, -OCH2CO-[(eta(5)-C5H4)FeCp], has replaced this key functional side chain, while keeping a good affinity for the estrogen receptor and an antiproliferative activity on cancer cells (MCF-7 and PC-3). Its mechanism of action is likely to be different from the antihormonal pathway followed by hydroxytamoxifen, and from the cytotoxicity observed for the ferrocifens. (C) 2006 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2006.11.016
• 作为产物：
  描述：

  1-(4-hydroxyphenyl)-1,2-bis(4-trimethylacetoxyphenyl)but-1-ene 、 2-chloro-1-ferrocenylethanone 在 KH 作用下， 以 四氢呋喃 为溶剂， 以41%的产率得到(C2H5)(C(p-trimethylacetoxyphenyl))2OCH2CO[(η5-C5H4)FeCp]
  参考文献：
  名称：

  Organometallic analogues of tamoxifen: Effect of the amino side-chain replacement by a carbonyl ferrocenyl moiety in hydroxytamoxifen

  摘要：

  Since the widely prescribed selective estrogen receptor modulator (SERM) tamoxifen encounters growing cases of resistance in long-term treatments, alternative drugs with different therapeutic scopes have to be developed. Many investigators have modified the triphenylethylene scaffold, but very few have changed its amino side chain, essential for the antiestrogenic activity. For the first time, a lipophilic and stable organometallic entity, -OCH2CO-[(eta(5)-C5H4)FeCp], has replaced this key functional side chain, while keeping a good affinity for the estrogen receptor and an antiproliferative activity on cancer cells (MCF-7 and PC-3). Its mechanism of action is likely to be different from the antihormonal pathway followed by hydroxytamoxifen, and from the cytotoxicity observed for the ferrocifens. (C) 2006 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2006.11.016